W e read with interest the article concerning the role of bispectral index (BIS) monitoring in intensive care by Bigham and colleagues. 1 As the authors noted in their article, over-sedation is associated with higher ventilator-associated pneumonia rates, and they also state that "BIS monitoring may be a useful adjunct in situations requiring neuromuscular blockade. There are incidences of awareness during tracheostomy insertion and other invasive procedures." We share the authors concerns regarding the possibility of both over-sedation and awareness during percutaneous tracheostomies carried out on the intensive care unit, and observed that in routine practice a high variability in the doses of sedation was given during this procedure. Up to 40% of patients receiving neuromuscular antagonist drugs in ICU are at higher risk of awareness. 2 To investigate whether BIS monitoring might be useful in the specific circumstance of percutaneous tracheostomy, when patients usually receive neuromuscular blocking drugs, we carried out a pilot randomised single-blinded control trial (with ethical approval) in our intensive care unit. Patients undergoing a percutaneous tracheostomy were randomised to control or intervention groups. Patients in the intervention group were sedated with alfentanil (0.05mg/kg/hr) and a propofol infusion targeting a BIS of 45-60 during the tracheostomy. Patients in the control group were also sedated with alfentanil (0.05 mg/kg/hr) and a propofol infusion, and the BIS was recorded with staff performing the tracheostomy blinded to the values. Patients were monitored with a BIS XP™ monitor (Covidien-Nellcor™, Colorado, USA) using adult BIS Quatro (Covidien-Nellcor™, Colorado, USA) monitoring electrodes placed on the forehead. We measured arterial blood pressure, total doses of propofol given during the procedure, and BIS values achieved in each group. We also measured how long it took for the patients to recover consciousness after the procedure.
As Bigham and colleagues identify, there are several conditions known to interfere with BIS monitoring, including traumatic brain injury. Patients with such conditions were excluded from the study. Patients receiving sedative drugs other than propofol and alfentanil prior to tracheostomy were also excluded. Ten patients were included in each group. Despite the patients in the intervention group maintaining a BIS between 45-60, we did not find any significant differences No patients were transferred to a tertiary centre for renal replacement therapy. The dialysis machine was returned to Oxford in November 2012 when supply chain of the CVVH filters and tubing had been secured. This solution to a shortterm supply issue worked well and helped the ICU cement closer bonds with our renal colleagues. Based on the magnitude of the earthquakes, the resulting damage to our suppliers' facilities led to supply constraints, but Baxter actively worked with our suppliers and customers to manage inventory while our suppliers prepared to resume operations. Baxter' s primary goal at all times was to do its best to maintain supply with these vital CRRT and therapeutic plasma exchange (TPE) products.
Throughout the supply-constrained period Baxter undertook a number of actions which are listed below:
All customers were informed of the situation as soon as Baxter UK was aware of the situation in Italy and the impact on our suppliers. A letter was sent out to all customers on 4th July 2012 informing them of the situation. From that date, regular communication via letter to all affected customers then followed with updates on the latest with regards to supply as due to the circumstances this was a rapidly changing situation. This communication continued until January 2013 when supply resumed as our suppliers had resumed their operations.
Baxter actively arranged alternatives to some of these affected supplies during the time of crisis and made these available to customers wherever possible.
We informed the MHRA and in turn the Department of Health as soon as we were aware of the potential impact to customers and patients. Several meetings were held over the period of the supply constraints to ensure that the latest information was shared with key individuals managing the situation so that we could best support ICU and hospitals to maintain patient treatment.
Baxter staff worked closely with all clinical customers to shift inventories and support hospitals who had higher usage of these products to ensure they had the ability to access products that may be held by other units in storage. We concluded that the use of BIS monitoring significantly reduced the time to awakening after percutaneous tracheostomy, despite there being no significant difference in the mean total dose of propofol administered, and may be a useful monitoring tool to avoid over-sedation or undersedation during this procedure.
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